SG11201407970VA - Modulation of hepatitis b virus cccdna transcription - Google Patents
Modulation of hepatitis b virus cccdna transcriptionInfo
- Publication number
- SG11201407970VA SG11201407970VA SG11201407970VA SG11201407970VA SG11201407970VA SG 11201407970V A SG11201407970V A SG 11201407970VA SG 11201407970V A SG11201407970V A SG 11201407970VA SG 11201407970V A SG11201407970V A SG 11201407970VA SG 11201407970V A SG11201407970V A SG 11201407970VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- lllll
- pennsylvania
- hbv
- cccdna
- Prior art date
Links
- 108091036055 CccDNA Proteins 0.000 title abstract 6
- 238000013518 transcription Methods 0.000 title abstract 3
- 230000035897 transcription Effects 0.000 title abstract 3
- 241000700721 Hepatitis B virus Species 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 108010033040 Histones Proteins 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 241000585703 Adelphia <angiosperm> Species 0.000 abstract 1
- 240000000724 Berberis vulgaris Species 0.000 abstract 1
- 235000016068 Berberis vulgaris Nutrition 0.000 abstract 1
- 235000014036 Castanea Nutrition 0.000 abstract 1
- 241001070941 Castanea Species 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 abstract 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 abstract 1
- 241000566107 Scolopax Species 0.000 abstract 1
- FWXAUDSWDBGCMN-DNQXCXABSA-N [(2r,3r)-3-diphenylphosphanylbutan-2-yl]-diphenylphosphane Chemical compound C=1C=CC=CC=1P([C@H](C)[C@@H](C)P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 FWXAUDSWDBGCMN-DNQXCXABSA-N 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000004049 epigenetic modification Effects 0.000 abstract 1
- 208000002672 hepatitis B Diseases 0.000 abstract 1
- 238000007726 management method Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000002831 pharmacologic agent Substances 0.000 abstract 1
- 230000003405 preventing effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
- C07K5/123—Tripeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
- C07K5/126—Tetrapeptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261654374P | 2012-06-01 | 2012-06-01 | |
| PCT/US2013/043691 WO2013181584A2 (en) | 2012-06-01 | 2013-05-31 | Modulation of hepatitis b virus cccdna transcription |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201407970VA true SG11201407970VA (en) | 2014-12-30 |
Family
ID=49674087
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201407970VA SG11201407970VA (en) | 2012-06-01 | 2013-05-31 | Modulation of hepatitis b virus cccdna transcription |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US9623071B2 (enExample) |
| EP (1) | EP2854832A4 (enExample) |
| JP (1) | JP6431478B2 (enExample) |
| KR (1) | KR101945578B1 (enExample) |
| CN (1) | CN104507488A (enExample) |
| AU (2) | AU2013267209B2 (enExample) |
| BR (1) | BR112014029697A2 (enExample) |
| CA (1) | CA2874828A1 (enExample) |
| HK (1) | HK1208823A1 (enExample) |
| IL (1) | IL235912A0 (enExample) |
| PH (1) | PH12014502659A1 (enExample) |
| SG (1) | SG11201407970VA (enExample) |
| WO (1) | WO2013181584A2 (enExample) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5977837B2 (ja) | 2011-12-21 | 2016-08-24 | ノヴィラ・セラピューティクス・インコーポレイテッド | Ｂ型肝炎抗ウイルス剤 |
| MX373711B (es) | 2012-08-28 | 2020-05-08 | Janssen Sciences Ireland Uc | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b. |
| WO2014074906A1 (en) * | 2012-11-09 | 2014-05-15 | Indiana University Research And Technology Corporation | Alternative uses for hbv assembly effectors |
| JP2016501531A (ja) | 2012-12-12 | 2016-01-21 | ザ・ブロード・インスティテュート・インコーポレイテッド | 配列操作および治療適用のための系、方法および組成物の送達、エンジニアリングおよび最適化 |
| ES2701749T3 (es) | 2012-12-12 | 2019-02-25 | Broad Inst Inc | Métodos, modelos, sistemas y aparatos para identificar secuencias diana para enzimas Cas o sistemas CRISPR-Cas para secuencias diana y transmitir resultados de los mismos |
| WO2014093701A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof |
| DK2961732T3 (en) | 2013-02-28 | 2017-07-10 | Janssen Sciences Ireland Uc | SULFAMOYLARYLAMIDS AND USE THEREOF AS MEDICINES TO TREAT HEPATITIS B |
| US8993771B2 (en) | 2013-03-12 | 2015-03-31 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
| CN105102451B (zh) | 2013-04-03 | 2018-09-18 | 爱尔兰詹森科学公司 | N-苯基-氨甲酰衍生物及其作为药物用于治疗乙型肝炎的用途 |
| JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
| SG10201710487VA (en) | 2013-06-17 | 2018-01-30 | Broad Inst Inc | Delivery, Use and Therapeutic Applications of the Crispr-Cas Systems and Compositions for Targeting Disorders and Diseases Using Viral Components |
| EP3725885A1 (en) | 2013-06-17 | 2020-10-21 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof |
| EP3825406A1 (en) | 2013-06-17 | 2021-05-26 | The Broad Institute Inc. | Delivery and use of the crispr-cas systems, vectors and compositions for hepatic targeting and therapy |
| WO2014204724A1 (en) | 2013-06-17 | 2014-12-24 | The Broad Institute Inc. | Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation |
| EP3011030B1 (en) | 2013-06-17 | 2023-11-08 | The Broad Institute, Inc. | Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation |
| KR102244937B1 (ko) | 2013-07-25 | 2021-04-27 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 글리옥사미드 치환된 피롤아미드 유도체 및 ｂ형 간염 치료용 의약으로서의 이의 용도 |
| DK3060547T3 (en) | 2013-10-23 | 2018-01-15 | Janssen Sciences Ireland Uc | CARBOXAMIDE DERIVATIVES AND USE THEREOF AS MEDICINES FOR TREATMENT OF HEPATITS B |
| WO2015089364A1 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Crystal structure of a crispr-cas system, and uses thereof |
| EP3080271B1 (en) | 2013-12-12 | 2020-02-12 | The Broad Institute, Inc. | Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems |
| BR112016013547A2 (pt) | 2013-12-12 | 2017-10-03 | Broad Inst Inc | Composições e métodos de uso de sistemas crispr-cas em distúrbios de repetições de nucleotídeos |
| KR20160089530A (ko) | 2013-12-12 | 2016-07-27 | 더 브로드 인스티튜트, 인코퍼레이티드 | Ｈｂｖ 및 바이러스 질병 및 질환을 위한 ｃｒｉｓｐｒｃａｓ 시스템 및 조성물의 전달，용도 및 치료적 적용 |
| WO2015089462A1 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for genome editing |
| EP4219699A1 (en) | 2013-12-12 | 2023-08-02 | The Broad Institute, Inc. | Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation |
| US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| US9181288B2 (en) | 2014-01-16 | 2015-11-10 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| EP3102225B1 (en) | 2014-02-05 | 2020-03-25 | Novira Therapeutics Inc. | Combination therapy for treatment of hbv infections |
| US11078193B2 (en) | 2014-02-06 | 2021-08-03 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| US9400280B2 (en) | 2014-03-27 | 2016-07-26 | Novira Therapeutics, Inc. | Piperidine derivatives and methods of treating hepatitis B infections |
| MX375407B (es) | 2014-06-20 | 2025-03-06 | Univ Drexel | Antígeno e de hepadnavirus marcado y su uso en el tamizado de sustancias antivirales. |
| EP3985115A1 (en) | 2014-12-12 | 2022-04-20 | The Broad Institute, Inc. | Protected guide rnas (pgrnas) |
| AU2015369725A1 (en) | 2014-12-24 | 2017-06-29 | Massachusetts Institute Of Technology | CRISPR having or associated with destabilization domains |
| US9884831B2 (en) | 2015-03-19 | 2018-02-06 | Novira Therapeutics, Inc. | Azocane and azonane derivatives and methods of treating hepatitis B infections |
| WO2016161268A1 (en) | 2015-04-01 | 2016-10-06 | Enanta Pharmaceuticals, Inc. | Hepatitis b antviral agents |
| US10738035B2 (en) | 2015-05-13 | 2020-08-11 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| WO2016205759A1 (en) | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation |
| RU2752834C2 (ru) | 2015-06-18 | 2021-08-09 | Те Брод Инститьют, Инк. | Мутации фермента crispr, уменьшающие нецелевые эффекты |
| US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| WO2017011552A1 (en) | 2015-07-13 | 2017-01-19 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| US10301255B2 (en) | 2015-07-22 | 2019-05-28 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| WO2017015451A1 (en) * | 2015-07-22 | 2017-01-26 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| KR101771309B1 (ko) * | 2015-07-24 | 2017-08-24 | 재단법인 목암생명과학연구소 | B형 간염 바이러스의 ｃｃｃＤＮＡ 형성 억제용 약학 조성물 |
| TW201718496A (zh) | 2015-09-29 | 2017-06-01 | 諾維拉治療公司 | B型肝炎抗病毒劑之晶型 |
| WO2017136403A1 (en) | 2016-02-02 | 2017-08-10 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| CN109069488B (zh) | 2016-03-07 | 2021-09-07 | 英安塔制药有限公司 | 乙型肝炎抗病毒剂 |
| CN109640980A (zh) | 2016-04-15 | 2019-04-16 | 诺维拉治疗公司 | 包含壳体装配抑制剂的组合和方法 |
| KR20190027814A (ko) | 2016-06-10 | 2019-03-15 | 이난타 파마슈티칼스, 인코포레이티드 | B형 간염 항바이러스제 |
| EP3484489B1 (en) | 2016-07-15 | 2025-06-18 | Viracta Subsidiary, Inc. | Hdac inhibitors for use with nk cell based therapies |
| RU2019120163A (ru) | 2016-12-13 | 2021-01-15 | Ам Сиенсес Инк | Фармацевтическая композиция для предупреждения или лечения гепатита B |
| TWI811236B (zh) | 2017-08-28 | 2023-08-11 | 美商因那塔製藥公司 | B型肝炎抗病毒試劑 |
| WO2019110589A1 (en) * | 2017-12-04 | 2019-06-13 | F. Hoffmann-La Roche Ag | Pyrrolo[2,3-b]pyrazine compounds as cccdna inhibitors for the treatment of hepatitis b virus (hbv) infection |
| WO2019113175A1 (en) | 2017-12-06 | 2019-06-13 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| TW201927789A (zh) | 2017-12-06 | 2019-07-16 | 美商因那塔製藥公司 | B型肝炎抗病毒試劑 |
| WO2019143902A2 (en) | 2018-01-22 | 2019-07-25 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| JP2021515769A (ja) | 2018-03-14 | 2021-06-24 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | カプシド集合調節剤の投薬レジメン |
| WO2019191166A1 (en) | 2018-03-29 | 2019-10-03 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| KR102273071B1 (ko) * | 2018-06-12 | 2021-07-05 | 주식회사 에이엠사이언스 | B형 간염 예방 또는 치료용 조성물 |
| WO2019240504A1 (en) * | 2018-06-12 | 2019-12-19 | Am Sciences Co., Ltd. | Modified oligonucleotides for inhibition of target gene expression |
| US10865211B2 (en) | 2018-09-21 | 2020-12-15 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| CN112888480A (zh) * | 2018-10-24 | 2021-06-01 | 豪夫迈·罗氏有限公司 | 用于治疗和预防乙型肝炎病毒疾病的新型三环化合物 |
| US11198693B2 (en) | 2018-11-21 | 2021-12-14 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| MA55020A (fr) | 2019-02-22 | 2021-12-29 | Janssen Sciences Ireland Unlimited Co | Dérivés d'amide utiles dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b |
| AR119732A1 (es) | 2019-05-06 | 2022-01-05 | Janssen Sciences Ireland Unlimited Co | Derivados de amida útiles en el tratamiento de la infección por vhb o de enfermedades inducidas por vhb |
| KR20220034736A (ko) | 2019-05-31 | 2022-03-18 | 비락타 서브시디어리 인크. | 히스톤 데아세틸라제 억제제를 사용하여 바이러스 관련 암을 치료하는 방법 |
| US11236111B2 (en) | 2019-06-03 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| WO2020247561A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
| US11472808B2 (en) | 2019-06-04 | 2022-10-18 | Enanta Pharmaceuticals, Inc. | Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents |
| US11738019B2 (en) | 2019-07-11 | 2023-08-29 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| US11236108B2 (en) | 2019-09-17 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| EP4037706A4 (en) * | 2019-10-02 | 2023-09-13 | University of Washington | Compositions and methods for treatment of hepatitis b virus infection |
| US11802125B2 (en) | 2020-03-16 | 2023-10-31 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
| EP4200419A2 (en) * | 2020-08-21 | 2023-06-28 | F. Hoffmann-La Roche AG | Use of a1cf inhibitors for treating hepatitis b virus infection |
| CN112274516B (zh) * | 2020-10-26 | 2022-08-05 | 中山大学附属第三医院 | 一种新型含碘抗病毒药物 |
| IT202100005054A1 (it) * | 2021-03-04 | 2022-09-04 | Azienda Ospedaliero Univ Di Parma | Composto farmaceutico per l’uso in un trattamento terapeutico dell’infezione cronica da hbv e metodo per l’identificazione di linfociti esauriti |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002051846A1 (en) | 2000-12-22 | 2002-07-04 | Zee, Ok Pyo | Apicidin-derivatives, their synthetic methods, and antitumor compositions containing the same |
| US20100009970A1 (en) * | 2008-03-19 | 2010-01-14 | Combinatorx (Singapore) Pte. Ltd. | Compositions and methods for treatment of viral diseases |
| US20110086869A1 (en) | 2009-09-24 | 2011-04-14 | The Trustees Of Boston University | Methods for treating viral disorders |
| WO2011113013A2 (en) * | 2010-03-11 | 2011-09-15 | Hemaquest Pharmaceuticals, Inc. | Methods and compositions for treating viral or virally-induced conditions |
-
2013
- 2013-05-31 JP JP2015515256A patent/JP6431478B2/ja not_active Expired - Fee Related
- 2013-05-31 KR KR1020147036640A patent/KR101945578B1/ko not_active Expired - Fee Related
- 2013-05-31 SG SG11201407970VA patent/SG11201407970VA/en unknown
- 2013-05-31 HK HK15109632.8A patent/HK1208823A1/xx unknown
- 2013-05-31 WO PCT/US2013/043691 patent/WO2013181584A2/en not_active Ceased
- 2013-05-31 BR BR112014029697A patent/BR112014029697A2/pt not_active Application Discontinuation
- 2013-05-31 US US14/435,675 patent/US9623071B2/en not_active Expired - Fee Related
- 2013-05-31 CN CN201380035280.3A patent/CN104507488A/zh active Pending
- 2013-05-31 CA CA2874828A patent/CA2874828A1/en not_active Abandoned
- 2013-05-31 EP EP13797412.7A patent/EP2854832A4/en not_active Withdrawn
- 2013-05-31 AU AU2013267209A patent/AU2013267209B2/en not_active Ceased
-
2014
- 2014-11-26 IL IL235912A patent/IL235912A0/en unknown
- 2014-11-28 PH PH12014502659A patent/PH12014502659A1/en unknown
-
2017
- 2017-04-10 US US15/483,711 patent/US10143720B2/en not_active Expired - Fee Related
- 2017-04-21 AU AU2017202675A patent/AU2017202675A1/en not_active Abandoned
-
2018
- 2018-08-28 US US16/115,298 patent/US20180369323A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL235912A0 (en) | 2015-01-29 |
| US20180369323A1 (en) | 2018-12-27 |
| BR112014029697A2 (pt) | 2017-08-08 |
| US9623071B2 (en) | 2017-04-18 |
| EP2854832A4 (en) | 2016-06-08 |
| WO2013181584A2 (en) | 2013-12-05 |
| US20170296619A1 (en) | 2017-10-19 |
| HK1208823A1 (en) | 2016-03-18 |
| WO2013181584A3 (en) | 2014-02-13 |
| PH12014502659A1 (en) | 2015-01-21 |
| AU2013267209B2 (en) | 2017-02-02 |
| KR20150022911A (ko) | 2015-03-04 |
| JP2015518055A (ja) | 2015-06-25 |
| CN104507488A (zh) | 2015-04-08 |
| JP6431478B2 (ja) | 2018-11-28 |
| KR101945578B1 (ko) | 2019-02-07 |
| EP2854832A2 (en) | 2015-04-08 |
| AU2013267209A1 (en) | 2014-12-18 |
| US10143720B2 (en) | 2018-12-04 |
| US20150265672A1 (en) | 2015-09-24 |
| CA2874828A1 (en) | 2013-12-05 |
| AU2017202675A1 (en) | 2017-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201407970VA (en) | Modulation of hepatitis b virus cccdna transcription | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
| SG11201407486PA (en) | Compositions and methods for modulating utrn expression | |
| SG11201906161VA (en) | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells | |
| SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201810423XA (en) | Pd-1 / pd-l1 inhibitors for cancer treatment | |
| SG11201900135YA (en) | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors | |
| SG11201907744QA (en) | Replacement of cytotoxic preconditioning before cellular immunotherapy | |
| SG11201408807YA (en) | Tm-enhanced blocking oligonucleotides and baits for improved target enrichment and reduced off-target selection | |
| SG11201808799SA (en) | Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors | |
| SG11201807252QA (en) | Anti-lag-3 antibodies | |
| SG11201808176TA (en) | Gene therapy for treating mucopolysaccharidosis type ii | |
| SG11201901658PA (en) | Beta-lactamase inhibitor compounds | |
| SG11201804814YA (en) | Materials and methods for delivering nucleic acids to cochlear and vestibular cells | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201804152RA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201407669QA (en) | Methods for improving safety of blood-brain barrier transport | |
| SG11201805570WA (en) | Systems and methods for long term transdermal administration | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201901834WA (en) | Micrornas as biomarkers for endometriosis | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201407859YA (en) | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists | |
| SG11201407372UA (en) | Nampt inhibitors |